PLRX Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc. (PLRX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $114.4K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Coulie Bernard | President and CEO | Sell 10b5-1 | 89,375 | $1.28 | $114.4K | 505,601 −15% of holding | |
| Cummings Keith Lamont | Chief Financial Officer | Sell 10b5-1 | 24,002 | $1.28 | $30.7K | 297,214 −7.5% of holding | |
| Cheung Lily | Chief Human Resource Officer | Sell 10b5-1 | 7,534 | $1.28 | $9.6K | 44,847 −14.4% of holding | |
| Kuo Minnie | Chief Operating Officer | Sell 10b5-1 | 6,917 | $1.28 | $8.9K | 37,806 −15.5% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.